newsfilter
← Latest News
Business Wire·

InVivo Therapeutics Announces FDA Acceptance of Preclinical Module in Support of Company's Complete HDE Submission

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the acceptance by the U.S. Food and Drug Administration (FDA) o